干细胞诱导分化、衍生配子研究及伦理学问题探讨

摘要
图/表
参考文献(30)
相关文章 (1)

全文: PDF (5574 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要干细胞诱导分化衍生配子研究,可以用于以下两个方面:其一,科学性研究活动,例如探索不孕不育症或配子形成过程等;其二,促进人体辅助生殖技术的科学发展。然而,该项技术研究的开展,亟待对涉及的伦理、法律及社会效应进行充分的权衡评价。本文围绕上述核心问题,针对干细胞源配子基础研究及人体生殖研究等方面展开论述,并就隐私保护、知情同意、过程管理等进行相关分析,以期为当前干细胞研究利益相关方的权利保护和伦理审查实践提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘军
	曾令烽
	包文虎
	曹烨
	潘建科
	关梓桐
	曹倩
	李晓彦
	王奇
	梁伟雄
	曾星

关键词 ：诱导多能干细胞, 衍生配子, 风险控制, 伦理学问题

Abstract：The recent study of stem cells induced differentiation for gametes could be used in two aspects as follows:first,for an exploration of scientific activities,such as infertility,formation of gamete;second,for the promotion of human assisted reproductive technology.However,the development of this technology calls for full evaluation and assessment involving ethical,legal and social effects.On the basis of the core problem and principles,this article attempted to discuss the issues such as ethical domains of basic study and human reproductive research focusing on stem cells induced differentiation for gametes,and further integrated privacy protection,informed consent and process control.We hope all these considerations could provide references to the better understanding of stem cells research and decision-making in ethical practice.

Key words： Induced pluripotent stem cells Differentiation for gametes Risk control Ethical issue

收稿日期: 2017-05-18

PACS:

R33

基金资助:国家自然科学基金项目(81473698),广东省财政厅项目([2014]157号),教育部博士点基金项目(20124425110004),国家科技重大专项(2012ZX09303009-003)。

作者简介: 刘军(1966-),男,主任医师,博士生导师;研究方向:中医骨科、干细胞和科技伦理学。

引用本文:

刘军, 曾令烽, 包文虎, 曹烨, 潘建科, 关梓桐, 曹倩, 李晓彦, 王奇, 梁伟雄, 曾星. 干细胞诱导分化、衍生配子研究及伦理学问题探讨[J]. 中国科技论坛, 2018(3): 152-158.
Liu Jun, Zeng Lingfeng, Bao Wenhu, Cao Ye, Pan Jianke, Guan Zitong, Cao Qian, Li Xiaoyan, Wang Qi, Liang Weixiong, Zeng Xing. Stem Cells Induced Differentiation for Reproductive Gamete and Concerning Ethical Consideration. , 2018(3): 152-158.

链接本文:

http://www.zgkjlt.org.cn/CN/Y2018/I3/152

[1]钱万强,陈涛,江海燕.基于文献计量学的国内外干细胞研究热点分析[J].中国科技论坛,2012(2):152-159.
[2]陈涛,钱万强.国内外干细胞研究和产业发展态势分析[J].中国科技论坛,2011(10):150-153.
[3]HAYASHI K,OGUSHI S,KURIMOTO K,et al.Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice[J].Science,2012,338(6109):971-975.
[4]HIKABE O,HAMAZAKI N,NAGAMATSU G,et al.Reconstitution in vitro of the entire cycle of the mouse female germ line[J].Nature,2016,539(7628):299-303.
[5]CYRANOSKI D.Mouse eggs made from skin cells in a dish[J].Nature,2016,538(7625):301.
[6]ZHOU Q,WANG M,YUAN Y,et al.Complete meiosis from embryonic stem cell-derived germ cells in vitro[J].Cell stem cell,2016,18(3):330-340.
[7]王珊珊,王宏起,高翔.我国干细胞产业技术标准化模式与策略研究[J].中国科技论坛,2014(10):54-59.
[8]高翔,王宏起,李玥.基于粗糙集的干细胞技术产业化潜力评价研究[J].中国科技论坛,2014(6):56-62.
[9]ISHII T,PERA R A.Creating human germ cells for unmet reproductive needs[J].Nature biotechnology,2016,34(5):470-473.
[10]HENDRIKS S,DONDORP W,DE WG,et al.Potential consequences of clinical application of artificial gametes:a systematic review of stakeholder views[J].Human reproduction update,2015,21(3):297-309.
[11]徐婕,周宁.公共财政支持的科研项目如何保障公众利益——来自美国加州干细胞研究项目的启示[J].中国科技论坛,2012(9):148-152.
[12]刘长秋.生物经济发展的法律需求及其立法原则研究[J].中国科技论坛,2014(3):48-52.
[13]HYUN I,WILKERSON A,JOHNSTON J,et al.Embryology policy:revisit the 14-day rule[J].Nature,2016:169-171.
[14]刘长秋,马彦.论人类遗传资源的国际法律地位——兼对中国立法之启示[J].中国科技论坛,2016(9):104-109.
[15]HYUN I.Policy:regulate embryos made for research[J].Nature,2014,509(7498):27-28.
[16]BREDENOORD A L,CLEVERS H,KNOBLICH J A.Human tissues in a dish:the research and ethical implications of organoid technology[J].Science,2017,355(6322).
[17]DALEY G Q,HYUN I,APPERLEY J F,et al.Setting global standards for stem cell research and clinical translation:the 2016 ISSCR guidelines[J].Stem cell reports,2016,6(6):787-797.
[18]《干细胞临床研究管理办法(试行)》解读.中华人民共和国国家卫生与计划生育委员会,2015[EB/OL].(2017-04-30).http://www.nhfpc.gov.cn/zwgk/jdjd/201508/e941634d667c4e25bae62566da537363.shtml.
[19]US Government 2009,Code of Federal Regulations Title 45,Part 46.101.b.2[EB/OL].(2017-04-30).https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/ohrpregulations.
[20]王太平,徐国彤,周琪,等.国际干细胞研究学会《干细胞临床转化指南》[J].生命科学,2009(5):747-756.
[21]COHEN I G,DALEY G Q,ADASHI E Y.Disruptive reproductive technologies[J].Science translational medicine,2017,9(372):eaag2959.
[22]罗会宇,雷瑞鹏.我们允许做什么?——人胚胎基因编辑之反思平衡简[J].伦理学研究,2017,38(2):111-117.
[23]TESTA G,HARRIS J.Ethics and synthetic gametes[J].Bioethics,2005,19(2):146-166.
[24]PALACIOSGONZáLEZ C,HARRIS J,TESTA G.Multiplex parenting:IVG and the generations to come[J].Journal of medical ethics,2014,40(11):752-758.
[25]NUSSBAUM M C.Hiding from humanity:disgust,shame,and the law[J].Dissent,2013,60(2):18.
[26]SMAJDOR A,CUTAS D.Artificial gametes and the ethics of unwitting parenthood[J].Journal of medical ethics,2014,40(11):748-751.
[27]BREDENOORD A L,PENNINGS G,WERT G D.Ooplasmic and nuclear transfer to prevent mitochondrial DNA disorders:conceptual and normative issues[J].Human reproduction update,2008,14(6):669-678.
[28]ILIOI E C,GOLOMBOK S.Psychological adjustment in adolescents conceived by assisted reproduction techniques:a systematic review[J].Human reproduction update,2014,21(1):84-96.
[29]CUTAS D,DONDORP W,SWIERSTRA T,et al.Artificial gametes:perspectives of geneticists,ethicists and representatives of potential users[J].Medicine,health care and philosophy,2014,17(3):339-345.
[30]HENDRIKS S,DONDORP W,DE W G,et al.Potential consequences of clinical application of artificial gametes:a systematic review of stakeholder views[J].Human reproduction update,2015,21(3):297-309.